### **RESEARCH ARTICLE**

Open Access

# Acute coronary syndrome patients admitted to a cardiology vs non-cardiology service: variations in treatment & outcome



Deirdre E. O'Neill<sup>1</sup>, Danielle A. Southern<sup>2</sup>, Colleen M. Norris<sup>1</sup>, Blair J. O'Neill<sup>1</sup>, Helen J. Curran<sup>3</sup> and Michelle M. Graham<sup>1,4\*</sup>

#### **Abstract**

**Background:** Specialized cardiology services have contributed to reduced mortality in acute coronary syndromes (ACS). We sought to evaluate the outcomes of ACS patients admitted to non-cardiology services in Southern Alberta

**Methods:** Retrospective chart review performed on all troponin-positive patients in the Calgary Health Region identified those diagnosed with ACS by their attending team. Patients admitted to non-cardiology and cardiology services were compared, using linked data from the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) registry and the Strategic Clinical Network for Cardiovascular Health and Stroke

**Results:** From January 1, 2007 to December 31, 2008, 2105 ACS patients were identified, with 1636 (77.7%) admitted to cardiology and 469 (22.3%) to non-cardiology services. Patients admitted to non-cardiology services were older, had more comorbidities, and rarely received cardiology consultation (5.1%). Cardiac catheterization was underutilized

(5.1% vs 86.4% in cardiology patients (p < 0.0001)), as was evidence-based pharmacotherapy (p < 0.0001). Following adjustment for baseline comorbidities, 30-day through 4-year mortality was significantly higher on non-cardiology vs. cardiology services (49.1% vs. 11.0% respectively at 4-years, p < 0.0001).

**Conclusion:** In a large ACS population in the Calgary Health Region, 25% were admitted to non-cardiology services. These patients had worse outcomes, despite adjustment for baseline risk factor differences. Although many patients were appropriately admitted to non-cardiology services, the low use of investigations and secondary prevention medications may contribute to poorer patient outcome. Further research is required to identify process of care strategies to improve outcomes and lessen the burden of illness for patients and the health care system.

Keywords: Acute coronary syndrome, Myocardial infarction, Specialist, Generalist, Non-cardiology

#### **Background**

Coronary Care Units (CCU) have been shown to contribute to a reduction in mortality in acute coronary syndrome (ACS) since the 1960's [1–9]. This is thought to be related to more intensive monitoring, timely recognition and treatment of life-threatening arrhythmias, and

more frequent prescription of evidence-based medications [4, 5].

Many groups have investigated the effect of specialist care versus generalist care in a variety of medical conditions, including chronic obstructive pulmonary disease, HIV, heart failure and acute myocardial infarction [10–15]. As medical expenditures escalate, increasing attention has been paid to the cost differences in the treatment of ACS by cardiologists versus non-cardiologists and the impact this may have on prognosis [16, 17].

Full list of author information is available at the end of the article



<sup>\*</sup> Correspondence: mmg2@ualberta.ca

<sup>&</sup>lt;sup>1</sup>Division of Cardiology and Department of Medicine, and Mazankowski Alberta Heart Insitute, University of Alberta, Edmonton, Canada <sup>4</sup>Division of Cardiology, University of Alberta, 2C2 WMC, 8440 112 St, Edmonton, AB T6G 2B7, Canada

To date, the literature has been inconsistent on the influence of non-cardiology management of ACS. Shreiber et al. found ACS patients admitted to a cardiology service were more likely to be treated with evidence-based secondary prevention medications. They were also more likely to receive angiogram and angioplasty [18]. Similarly, Nash and colleagues demonstrated that ACS patients treated by a cardiologist had a 30% lower inhospital mortality compared to those treated by a general practitioner or internist. [19] However, other studies have shown that the average patient admitted to a cardiology ward is much younger, with fewer comorbidities and an attenuated benefit with specialist treatment is seen when outcomes are adjusted for baseline risk factor differences [10, 20].

With the advancing age of the population, multiple non-cardiac comorbidities may be present in ACS patients, making it at times more appropriate to admit certain ACS patients to non-cardiology services. In addition, should a patient admitted with a different medical problem subsequently develop an ACS during hospitalization, transfer to cardiology may not be ideal.

Our objective was to evaluate the investigation and treatment of ACS patients admitted to a cardiology service versus a non-cardiology service, to determine whether admitting service was associated with the patient outcome of mortality or re-hospitalization. We also sought to evaluate any differences in the processes of care on these services.

#### **Methods**

Calgary is a city in Alberta, Canada with a population of 1,149,552 (2013 Census). The Calgary Health Region has three major hospitals, of which two are regional centers and one is a tertiary care center with cardiac catheterization capabilities. All three hospitals in this region are teaching hospitals affiliated with the Faculty of Medicine at the University of Calgary.

Cardiac troponin is a protein complex that regulates contraction of cardiac muscle. The measurement of troponin is essential to the work-up of ACS and it is currently accepted that a cardiac troponin value exceeding the 99<sup>th</sup> percentile for a reference control group, in the setting of clinical history suggestive of ACS, is consistent with myocardial necrosis [21]. Therefore over a period of January 1, 2007 to December 31, 2008, all inpatients with positive troponin values within the Calgary Health Region were identified. This time period was chosen as the value of troponin in the diagnosis of ACS was wellestablished and therefore it would be ordered on patients where the diagnosis of ACS was being considered. At the time of data collection, the Calgary Health Region was measuring cardiac troponin T (cTnT), using the Roche Elecsys 2010 Modular Analytics E170. Normal value for troponin T using this assay is <0.03 nm/L and reported values of 0.03-40.0 nm/L exist. This compilation of standardized laboratory data therefore provided us the opportunity to identify individuals from all hospitals in Calgary who have undergone cTnT testing. Outside of the Calgary Health Region, troponin measurements are performed using multiple assays and were not available in a central repository. Therefore, patients whose primary residence was outside the Calgary Health Region or those transferred from institutions outside the region were excluded from the analysis. Patients whose troponin elevations occurred around the time of elective PCI or as a result of cardiac surgery or an electrophysiology procedure were also excluded.

A retrospective chart review, completed by an individual with medical training and specific knowledge of cardiovascular disease, was performed on all troponinpositive patients, identifying those the admitting service documented ACS as the cause of the elevated troponin. Further data on diagnostic tests, medications prescribed and mortality was then collected using the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) registry as well as Discharge Admission Data, provided by the Cardiovascular Health & Stroke Strategic Clinical Network of Alberta Health Services. In addition, an experienced cardiologist, blinded to all patient data, interpreted all electrocardiograms (ECG) performed around the time of the troponin elevation. We compared the use of specific cardiac investigations and treatments of those patients admitted to a cardiology service, with those admitted to a noncardiology service. Additionally, we compared mortality and re-hospitalization, to see whether outcome differences existed between these two groups.

#### Data sources

APPROACH is a population based clinical registry, that captures all patients undergoing cardiac catheterization in Alberta, Canada (2013 Census Population 3,828,484) since 1995 and follows them longitudinally to determine patient outcome [22]. Within the APPROACH database there are several modules; including an admission module which tracks all patients (regardless of having undergone cardiac catheterization) admitted with ACS (STEMI, NSTEMI, UA) across Southern Alberta. The APPROACH registry also contains detailed information regarding patient demographics, cardiac risk factors, comorbidities, and results of cardiac catheterization and revascularization procedures. Comorbidities are subsequently verified through a data enhancement procedure to ensure comorbidity data are accurate and there are no missing data [23, 24]. Mortality data for all patients in the database is ascertained through semiannual linkage to the Alberta Bureau of Vital Statistics.

The Cardiovascular Health & Stroke Strategic Clinical Network is an Alberta-wide team of healthcare professionals, researchers and policy makers who are knowledgeable about cardiovascular health and work to improve its prevention, treatment and management, through accessing and supporting research. Their support provided access to diagnostic tests including echocardiograms, myocardial perfusion imaging and CT scans and also allowed linkage of administrative data for readmissions.

#### Statistical analysis

Patients were grouped into those admitted to cardiology service, including those admitted to a cardiology ward or coronary care unit, and those admitted to a non-cardiology service, including all other services. The non-cardiology service patients were admitted to generalist or specialist physicians in a field other than cardiology. Baseline clinical characteristics were compared using chi-square tests. Kaplan Meier plots and log-rank tests were used to determine and compare crude mortality rates for these two groups. Mortality was then adjusted for age, sex and Charlson comorbidity index.

The Charlson comorbidity index is a weighted index that categorizes patients based upon comorbidities and the risk of mortality or resource use associated with such comorbidities. The sum of all of the weights results in an overall comorbidity score and is used to predict 10-year mortality. This index was first published in 1987 and has since been modified by various groups to include more comorbidity categories and age [25–27].

Analyses were performed using SAS, version 9.3 (Cary, NC).

#### Results

From January 1, 2007 to December 31, 2008, 4,860 patients with a positive cardiac troponin T were admitted to hospital in the Calgary Health Region. Of these, the attending team diagnosed 2,105 (43.4%) as having occurred as a result of ACS. Of those deemed to have had an ACS, 1,636 (77.7%) were admitted to a cardiology service and 469 (22.3%) were admitted to a non-cardiology service.

Table 1 shows the baseline characteristics of both patient groups. Those admitted to non-cardiology services were significantly older (79.6 years vs. 62.9 years, p < 0.0001), with more comorbidities, with the exception of hypertension and current smoking.

Of those admitted to a non-cardiology service, family medicine, nephrology and internal medicine were the most common admitting services, at 45%, 21.3% and 17.7% respectively. Despite the documented diagnosis of ACS, very few cardiology consultations and transfers of care occurred, with only 4.5% of patients admitted to

**Table 1** Baseline characteristics

Characteristic	Cardiology service N = 1636	Non-cardiology service <i>N</i> = 469	<i>P</i> -value
Mean Age (Std dev.)	62.9 (13.4)	79.6 (11.9)	<0.0001
Male sex	1178 (72.0)	240 (51.2%)	< 0.0001
Comorbidities			
Cerebrovascular Disease	21 (1.3%)	51 (10.9%)	<0.0001
Diabetes	340 (10.8%)	151 (32.2%)	< 0.0001
Hypertension	885 (54.1%)	218 (46.5%)	0.004
Hyperlipidemia	317 (19.4%)	14 (3.0%)	<0.0001
Peripheral vascular disease	25 (1.5%)	26 (5.5%)	<0.0001
Heart Failure	150 (9.2%)	176 (37.5%)	<0.0001
Prior MI	60 (3.7%)	23 (4.9%)	0.225
Pulmonary Disease	67 (4.1%)	100 (21.3%)	< 0.0001
Malignancy	26 (1.6%)	63 (13.4%)	<0.0001
Liver/GI Disease	13 (0.8%)	25 (5.3%)	< 0.0001
Renal Disease	83 (5.1%)	151 (32.2%)	< 0.0001
Current Smoker	242 (14.8%)	22 (4.7%)	<0.0001
Dementia	25 (1.5%)	66 (14.1%)	< 0.0001

Std dev standard deviation, MI myocardial infarction, GI gastrointestinal

non-cardiology services receiving a cardiology consult and subsequent transfer to a cardiology service and only 0.6% receiving consultation alone (Table 2).

When an experienced cardiologist analyzed all ECGs of those admitted with ACS, 3.2% of those admitted to cardiology and 4.1% admitted to a non-cardiology service did not have an ECG performed (NS). Of the ECG changes identified, ST segment changes (elevation or depression) occurred significantly more often in those patients admitted to cardiology, whereas T wave abnormalities were most common in those admitted to non-cardiology services. Additionally, more patients admitted to non-cardiology services did not have a follow-up ECG performed (5.1% vs. 24.7%, p < 0.0001) (Table 3).

**Table 2** Admitting service and consultation

Characteristics	Non-cardiology service $N = 469$		
Admitting Physician Service			
Family Medicine	211 (45.0%)		
Nephrology	100 (21.3%)		
Internal Medicine	83 (17.7%)		
Critical Care	47 (10.0%)		
Neurology	18 (3.8%)		
Surgery	10 (2.1%)		
Cardiology Consult			
Consulted + transferred	21 (4.5%)		
Consulted (no transfer)	3 (0.6%)		

Table 3 Investigations & treatment

Investigations	Cardiology service $N = 1636$	Non-cardiology service $N = 469$	P-value
ECG Findings			
No ECG	53 (3.2%)	19 (4.1%)	0.455
ECG Changes			
ST elevation	685 (41.9%)	34 (7.3%)	<0.0001
ST depression	417 (25.5%)	77 (16.4%)	<0.0001
T wave changes	575 (35.2%)	151 (32.2%)	0.312
Bundle branch block	123 (7.5%)	55 (11.7%)	0.004
Dynamic ECG Changes	117 (7.2%)	117 (25.0%)	<0.0001
No follow-up ECG	84 (5.1%)	116 (24.7%)	<0.0001
Troponin Values			
Mean (Std. Dev.)	1.69 (3.53)	0.48 (1.01)	<0.0001
Minimum	0.10	0.10	
Maximum	39.40	11.89	
Tests Performed			
Angiogram during index admission	86.4%	5.1%	<0.0001
MIBI	4.5%	2.8%	0.103
Echocardiogram	2.4%	43.3%	<0.0001
CT Chest	0	8.5%	<0.0001
Medications			
Aspirin	91.9%	80.8%	<0.0001
Clopidogrel	83.3%	31.8%	<0.0001
Beta Blocker	84.4%	73.6%	<0.0001
Ace Inhibitor	74.9%	62.9%	<0.0001
Statin	79.1%	56.9%	<0.0001

ECG electrocardiogram, ST ST segment, Std Dev Standard deviation, MIBI technetium sestamibi myocardial imaging scan, CT computerized tomography

Cardiac troponin T values were on average higher in those admitted to cardiology (1.69  $\mu$ m/l vs. 0.48  $\mu$ m/l, p < 0.0001), as were maximum troponin values achieved (39.40  $\mu$ m/l vs. 11.89  $\mu$ m/l, p < 0.0001). Those admitted to cardiology underwent angiogram significantly more often, with 86.4% undergoing angiogram on their index admission, compared to 5.1% in those admitted to non-cardiology services. Myocardial perfusion scans were performed infrequently on index admission in both the cardiology and non-cardiology groups. Echocardiogram and CT chest to rule out pulmonary embolism were more common in those patients admitted to non-cardiology services (2.4% vs. 43.3% and 0 vs. 8.5%, respectively, both p values <0.0001), as seen in Table 3.

Through retrospective chart review, the use of evidence-based medications for secondary prevention was identified. Aspirin, clopidogrel, beta blockers, ACE inhibitors and statin drugs were all used significantly less often in those admitted to a non-cardiology service when compared to those admitted to cardiology (Table 3).

As shown in Table 4, the 30-day mortality was significantly lower for patients admitted to cardiology, compared to those admitted to a non-cardiology service (2.6% vs. 20.3%, respectively, p < 0.0001). Mortality through to 4-years remained higher in those admitted to a non-cardiology service (11% vs 49.1%, respectively, p < 0.0001). This is also represented in the Kaplan Meier survival curve presented in Fig. 1. In addition, 1-year readmission rates were also significantly higher for those admitted to a non-cardiology service (26.7% vs. 39.4%, p < 0.0001).

When outcomes are adjusted for age, sex and Charlson comorbidity index, 30-day through to 4-year point estimates for mortality remain significant for those admitted to a non-cardiology service (Table 4). The odds ratio for mortality at 30-days in the non-cardiology group is 3.33 (95% CI 2.42-4.59) and is still significant at 1.70 (95% CI 1.47-1.96) at 4-years when compared to the cardiology group.

#### **Discussion**

We have found that in a modern major metropolitan region, about 25% of patients diagnosed with ACS were admitted to non-cardiology services. In keeping with previous literature, these patients were on average older and had more comorbidities. Our findings support the "specialist effect" for patient outcome, as even after adjustment for age, sex and baseline risk factor differences, we found short and longer term mortality to be significantly higher for those admitted to a non-cardiology service, as compared to those admitted to cardiology.

Previous literature has shown superior treatment and outcome for ACS patients treated by cardiologists as compared to non-cardiology-trained physicians [18, 19]. However, the ACS patient population admitted to cardiology is often younger, with fewer comorbidities and can result in an attenuated mortality benefit [10, 20]. In accordance with the literature, our study showed patients admitted to cardiology were starkly different from those admitted to non-cardiology services. Patients on non-cardiology services were older with more numerous comorbidities, including cerebrovascular disease, diabetes, pulmonary disease, malignancy and renal disease. However, even with adjustment, mortality was significantly higher in patients treated by non-cardiology services, suggesting outcome is also associated with admitting services.

Dynamic ECG changes were common in those admitted to non-cardiology services, occurring in 25% of patients. While occurring significantly less frequently than in the cardiology group, ST elevation still occurred in over 7% of the patients and ST depression occurred in 16%. However, only 5% underwent angiogram during their index admission, and less than 3% underwent non-invasive risk stratification with myocardial perfusion

**Table 4** Mortality

Outcome	Cardiology service N = 1636	Non-cardiology service $N = 469$	<i>P</i> -value	Crude OR (95% CI)	Adjusted <sup>a</sup> OR (95% CI)
30-day mortality	43 (2.6%)	95 (20.3%)	<0.0001	4.19 (3.19,5.49)	3.33 (2.42,4.59)
1-yr mortality	62 (3.9%)	140 (31.5%)	< 0.0001	3.39 (2.89,3.99)	2.25 (1.86,2.72)
2-yr mortality	92 (5.7%)	173 (39.0%)	< 0.0001	3.25 (2.82,3.74)	2.06 (1.75,244)
3-yr mortality	140 (8.7%)	200 (45.1%)	<0.0001	2.93 (2.58,3.33)	1.83 (1.58,2.13)
4-yr mortality	177 (11.0%)	218 (49.1%)	< 0.0001	2.80 (2.48,3.16)	1.70 (1.47,1.96)
30-day readmission	150 (9.3%)	59 (13.3%)	0.014		
1-yr readmission	430 (26.7%)	175 (39.4%)	<0.0001		


Yr year

<sup>a</sup>Adjusted for age, sex and Charlson comorbidity index Reference group = cardiology ward

imaging. This may be the result of the infrequent cardiology consultation noted in this group, as in the Calgary Health Region, a cardiology consultation is required in order to have an angiogram performed. Follow-up ECGs were also completed less frequently, with 24.7% having no follow-up ECG performed on a non-cardiology service, as compared to only 5.1% in the cardiology group (<0.0001). This allows the possibility for further signs of ischemia to have been missed in the period of time following the recognized troponin elevation.

Another process of care difference was identified in the use of echocardiogram. Those on non-cardiology services underwent echocardiogram more frequently than those admitted to cardiology. In the Calgary health region, at the time of data collection, standard practice was to perform a left ventriculogram and quantitative ejection fraction calculation at the time of angiogram, rather than echocardiogram, which was usually left to outpatient follow up visits. This likely accounts for the discrepant use of this test.

The differences outlined clearly demonstrate divergent processes of care used for patients admitted to cardiology versus non-cardiology services. It is possible that



patients admitted to non-cardiology services were not candidates for invasive investigation with cardiac catheterization. However, secondary prevention medications have few adverse effects compared to their benefits and were still significantly underprescribed. Multiple studies support the use of beta-blockers, statins and ASA as secondary prevention medications in the elderly and even in the very elderly (>80 years) population [28–33]. Therefore current evidence would support considering the use of these medications on an individual basis where appropriate.

The decision to treat patients with ACS on a noncardiology service may be appropriate in many cases, due to comorbidities and/or other acute diagnoses that benefit from the expertise of generalists or noncardiology subspecialists. However, the investigation and management of these patients could potentially be improved with more formal or defined collaborative consultation with cardiology. Willison et al. found that patients with acute myocardial infarction treated by a generalist with cardiology consultation had similar treatment to those treated by a cardiologist alone [34]. Improved patient outcome with consultation has also been shown in other medical specialties, with several studies finding improved mortality associated with infectious disease consultation [35-37]. Therefore, as Willison et al. concluded, in the generalist/ specialist care debate, the focus should be on improving consultation between generalists and specialists to improve quality of care [34].

We believe that we have identified an important process of care issue for ACS patients admitted to non-cardiology services. Standardized order sets and decision-support tools present physicians with a template for ordering diagnostic tests, medications and other items, based upon current evidence. Standardized order sets have been shown to improve quality of care, adherence to guideline-based therapies and in many cases, decrease mortality [38–42]. More specifically, Ellerbeck et al. found the use of standardized order sets significantly increased the use of aspirin and beta blockers on admission and discharge

of ACS patients and Milani et al. found computerized decision support increased the likelihood of achieving so-called "perfect care" in ACS and was an independent predictor of survival [42, 43]. With the variation in outcome based upon admitting service seen in our study, the introduction of such a processes throughout all areas of the hospital, triggering, for example, a cardiology consult or the use of certain evidence-based medications, could result in more standardized treatment of all ACS patients, regardless of care location. A quality improvement study comparing the outcome of patients with ACS before and after introduction of a hospital-wide ACS standardized order set could be helpful in promoting uptake of such a process of care change in the future.

This study does have limitations. It is an observational study and therefore residual confounding can occur. In particular, goals of care were not routinely collected; therefore it is possible that patients were not investigated because of pre-stated goals of care requesting to forgo aggressive medical management. However, this is not likely the majority of our cohort, given survival beyond hospitalization. In addition, troponins were not collected in an unselected manner, but were rather ordered by the attending service, when considered indicated. Certainly, it is possible that other ACS patients may have remained undiagnosed due to lack of troponin measurement. Additionally, we determined the diagnosis of ACS via retrospective chart review. It is possible that the some of the patients in our study may have actually experienced a type II MI, or another cause of troponin elevation. However, rightly or wrongly, the admitting team felt that the diagnosis was ACS, and their process of care was evaluated accordingly. Lastly, it is difficult to completely elucidate why a patient was admitted to a non-cardiology service or why cardiology consultation occurred so infrequently via chart review as this was not well documented. However, with such few cardiology consultations having occurred, it is clear that this decision is often being made without the input of cardiology.

#### **Conclusion**

In conclusion, one quarter of ACS patients admitted to tertiary care teaching hospitals in a major metropolitan city, were admitted to non-cardiology services. These patients were on average older and had more comorbidities. Despite a diagnosis of ACS, cardiology consultation occured rarely, and significantly fewer evidence-based secondary prevention medications were prescribed. Significantly worse outcomes were identified for these patients, even after adjustment for age, sex and comorbidity. Although many of these patients may be appropriately treated on services other than cardiology, the low use of investigations and secondary prevention medications may be contributing to the poorer outcomes.

Therefore, additional work is necessary to standardize the investigation and treatment of ACS and to encourage collaboration between specialties in order to improve outcomes and lessen the burden of illness for patients and the health care system.

#### **Abbreviations**

ACE: Angiotensin converting enzyme; ACS: Acute coronary syndromel; APPROACH: Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease; CCU: Coronary care units; CT: Computerized tomography; cTnT: Cardiac troponin T; ECG: Electrocardiogram; NSTEMI: Non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; UA: Unstable angina

#### Acknowledgements

Not applicable.

#### **Funding**

The paper was funded by a grant from the Institute of Circulatory and Respiratory Health provided to Dr Michelle Graham. CIHR was not involved in study design, interpretation of data or writing of the manuscript.

#### Availability of data and materials

Alberta Health is the custodian of the registry and administrative data used in this study and the research agreement required by the Health Information Act was followed. The data cannot be released because the raw files contain unique identifiers required to create the patient cohort.

#### Authors' contributions

DEO wrote the manuscript and interpreted the data included in the final manuscript. DS performed all statistical analysis, assisted with interpretation of data and critical revision of the manuscript. BJO and CN participated in design, data interpretation and critical manuscript revision. HJC re-interpreted all ECGs and participated in critical manuscript revision. MMG envisioned the study, obtained funding and supervised all aspects of the study. All authors read the final manuscript and were supportive of its submission for publication.

#### **Competing interests**

The authors declare that they have no competing interests.

#### Consent for publication

Not applicable.

#### Ethics approval and consent to participate

Ethics approval was obtained by the Health Research Ethics Board at the University of Alberta (Pro00011838). The ethics board granted a waiver of consent for this study given the retrospective chart review and no patient contact.

#### Sources of support

Supported by a grant from the Canadian Institutes of Health Research (CIHR).

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### **Author details**

<sup>1</sup>Division of Cardiology and Department of Medicine, and Mazankowski Alberta Heart Insitute, University of Alberta, Edmonton, Canada. <sup>2</sup>Department of Public Health Sciences, University of Calgary, Calgary, Canada. <sup>3</sup>Division of Cardiology and Department of Medicine, Dalhousie University, Halifax, Canada. <sup>4</sup>Division of Cardiology, University of Alberta, 2C2 WMC, 8440 112 St, Edmonton, AB T6G 2B7, Canada.

## Received: 5 May 2016 Accepted: 5 May 2017 Published online: 16 May 2017

#### References

- Rotstein Z, Mangelzweig L, Lavi M, Gottlieb S, Hod H. Does the coronary care unit improve prognosis of patients with acute myocardial infarction? Eur Heart J. 1999;20(11):813–8.
- Karlson BW, Herlitz J, Wiklund D, Petterson P, Hallgren P, Hjalmarson A. Characteristics and prognosis of patients with acute myocardial infarction in relation to whether they were treated in the coronary care unit or in another ward. Cardiology. 1992;81(2–3):134–44.
- Sagie A, Rotenberg Z, Weinberger I, Fuchs J, Agmon J. Acute transmural myocardial infarction in elderly patients hospitalized in the coronary care unit versus the general ward. J Am Geriatr Soc. 1987;35(10):915–9.
- Lawson-Matthew PJ, Wilson AT, Woodmansey PA, Channer KS.
   Unsatisfactory management of patients with myocardial infarction admitted
  to general medical wards. J Roy Coll Physicians (London). 1994;28(1):49–51.
- Amit G, Goldman S, Ore L, Low M, Kark JD. The association between hospital department, medical treatment and outcome in acute myocardial infarction. JMAJ. 2003;5(4):255–9.
- Chapman BL. Effect of coronary care on myocardial infarct mortality. Br Heart J. 1979;42:386–95.
- 7. Fuster V. Myocardial infarction and coronary care units. JACC. 1999;34(7):1851–3.
- 8 Fagin D, Anandiah KM. The coronary care unit and mortality from myocardial infarction: A continued evaluation. JAGS. 1971;19(8):675–86
- 9 Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two-year experience with 250 patients. Am J Cardiol. 1967;20:457–464.
- Ayanian J, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. New Engl J Med. 1994;331(17):1136–42.
- 11 Fendrick AM, Hirth RA, Chernew ME. Differences between generalist and specialist physicans regarding *Helicobacter pylori* and peptic ulcer disease. Am J Gastroenterol. 1996;91(8):1544–8.
- 12 G Diaz-Fuentes, V Lakshmi, S Blum, S Sy, E Escalera. Chronic Obstructive Pulmonary Disease: Comparison of Care by Specialists and Generalists in an Inner-City Hospital. The Internet Journal of Pulmonary Medicine. 2004;5(1):1–6.
- 13 Stone VE, Mansourati FF, Poses RM, Mayer KH. Relation of physician specialty and HIV/AIDS experiences to choice of guideline-recommended antiretroviral therapy. J Gen Intern Med. 2001;16(6):360–8.
- 14 Chin MH, Friedmann PD, Cassel CK, Lang RM. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med. 1997;12(9):523–30.
- 15 Ezekowitz JA, van Walraven CV, McAlister FA, Armstrong PW, Kaul P. Impact of specialist follow-up in outpatients with congestive heart failure. CMAJ. 1995;172(2):189–94.
- 16 Donohoe MT. Comparing generalist and specialty care: discrepancies, deficiencies and excesses. Arch Intern Med. 1998;158(15):1596–608.
- 17 Greenfield S, Nelson EC, Zubkoff M, et al. Variations in resource utilization among medical specialties and systems of care. Results from the medical outcomes study. JAMA. 1992;267(12):1624–30.
- 18 Schreiber TL, Elkhatib A, Grines CL, O'Neill WW. Cardiologist versus internist management of patients with unstable angina: treatment patterns and outcomes. JACC. 1995;26(3):577–82.
- 19 Nash IS, Corrato RR, Dlutowski MJ, O'Connor JP, Nash DB. Generalist versus specialist care for acute myocardial infarction. Am J Cardiol. 1999;83(5):650–4.
- 20 Jollis JG, DeLong ER, Peterson ED, et al. Outcome of acute myocardial infarction according to the specialty of the admitting physician. NEJM. 1996;335(25):1880–7.
- 21 Mahajan VS, Jarolim P. How to interpret elevated cardiac troponin levels. Circulation. 2011;124(21):2350–4.
- 22 Ghali WA, Knudtson ML. Overview of APPROACH the Alberta Provincial Program for Outcome Assessment in Coronary Heart Disease. Can J Cardiol. 2000;16(10):1225–30.
- 23 Norris CM, Ghali WA, Knudtson ML, Naylor CD, Saunders LD. Dealing with missing data in observational health care outcome analyses. J Clin Epidemiol. 2000;53(4):377–83.
- 24 Faris PD, Ghali WA, Brant R, Norris CM, Galbraith PD, Knudtson ML. APPROACH Investigators. Multiple imputation versus data enhancement for

- dealing with missing data in observational health care outcome analyses. J Clin Epidemiol. 2002;55(2):184–91.
- 25 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
- 26 Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.
- 27 Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. JACE. 1994;47(11):1245–51.
- 28 Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996;124(3):296–8.
- 29 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
- 30 Chen J, Marciniak TA, Radford M, Wang Y, Krumholz HM. Beta blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. J Am Coll Cardiol. 1999;34(5):1388–94.
- 31 Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers effective in elderly patients who undergo coronary revascularization for acute myocardial infarction? Arch Intern Med. 2000;160(7):947–52.
- 32 Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;8934(344):1383–9.
- 33 Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchial bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37–45.
- 34 Willison DJ, Soumerai SB, McLaughlin TJ, et al. Consultation between cardiologists and generalists in the management of acute myocardial infarction. Implications for quality of care. Arch Intern Med. 1998;158(16):1778–83.
- 35 Schmitt S, McQuillen DP, Nahass R, Martinelli L, Rubin M, Schwebke K, Petrak R, Ritter JT, Chansolme D, Slama T, Drozd EM, Braithwaite SF, Johnsrud M, Hammelman E. Infectious diseases specialty intervention is associated with decresased mortality and lower healthcare costs. Clin Infect Dis. 2014;58(1):22–8.
- 36 Rieg S, Kupper MF. Infectious diseases consultations can make the difference: A brief review and a plea for more infectious disease specialists in Germany. Infection. 2016;44:159–66.
- 37 Paulsen J, Solligard E, Damas JK, DeWan A, Asvold BO, Bracjen MB. The impact of infectious disease consultation for staphylococcus aureus bloodstream infections: A systematic review. Open Forum Infect Dis. 2016;3(2):ofw048.
- Micek ST, Roubinian N, Heuring T, et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med. 2006;34(11):2707–13.
- 39 Reingold S, Kulstad E. Impact of human factor design on the use of order sets in the treatment of congestive heart failure. Acad Emerg Med. 2007;14(11):1097–105.
- 40 Fishbane S, Niederman MS, Daly C, et al. The impact of standardized order sets and intensive clinical case management on outcomes in communityacquired pneumonia. Arch Intern Med. 2007;167(15):1664–9.
- 41 Mayorga CA, Rockey DC. Clinical utility of a standardized electronic order set for the management of acute upper gastrointestinal hemorrhage in patients with cirrhosis. Clin Gastroenterol Hepatol. 2013;11:1342–8.
- Milani RV, Lavie CJ, Dornelles AC. The impact of achieving perfect care in acute coronary syndrome: the role of computer assisted decision support. Am Heart J. 2012;164(1):29–34.
- 43 Ellerbeck EF, Bhimaraj A, Hall S. Impact of organizational infrastructure on b-blocker and aspirin therapy for acute myocardial infarction. Am Heart J. 2006;152:579–84.